Roberto Bellucci

TL;DR: The findings support the clinical evaluation of low-dose IL-2 to selectively modulate CD4+CD25+ Tregs and increase expression of FOXP3 in vivo.

TL;DR: It is indicated that patients with active cGVHD have reduced frequencies of Tregs but the function of these cells remains normal, and these findings support the development of new strategies to increase the number of T Regs following allogeneic hematopoietic stem cell transplantation.

TL;DR: The results show that NK cell activation and secretion of IFNγ results in activation of JAK1, JAK2 and STAT1 in tumor cells, resulting in rapid up-regulation of PD-L1 expression, suggesting that JAK pathway inhibitors as well as PD-1 and PD- L1 antibodies may work synergistically with other immune therapies by preventing IFN-induced inhibition of NK cell-mediated tumor cell lysis.

TL;DR: It is demonstrated that B-cell maturation antigen (BCMA), a transmembrane receptor of the tumor necrosis factor (TNF) superfamily, is a target of donor B- cell immunity in patients with myeloma who respond to DLI.

TL;DR: It is demonstrated that the GVM response is associated with antibody responses to highly expressed myeloma-associated antigens, and an association between antibody response and time of best response after DLI is shown.